Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Preferred Stock Liabilities (2016)

Voyager Therapeutics' Preferred Stock Liabilities history spans 2 years, with the latest figure at $36.1 million for Q4 2016.

  • For Q4 2016, Preferred Stock Liabilities changed 0.13% year-over-year to $36.1 million; the TTM value through Dec 2016 reached $36.1 million, changed 0.13%, while the annual FY2016 figure was $36.1 million, 0.13% changed from the prior year.
  • Preferred Stock Liabilities for Q4 2016 was $36.1 million at Voyager Therapeutics, roughly flat from $36.1 million in the prior quarter.
  • Across five years, Preferred Stock Liabilities topped out at $59.9 million in Q3 2015 and bottomed at $36.1 million in Q4 2015.